The acute kidney injury (AKI) treatment market has witnessed significant growth, attaining a value of USD 44.23 billion in 2023. AKI, also known as acute renal failure, is a sudden loss of kidney function that occurs within hours or days. The condition requires prompt medical attention, as it can lead to severe complications if left untreated. The AKI treatment market is projected to grow at a compound annual growth rate (CAGR) of 6.2% during the forecast period of 2024-2032, with an expected market value of USD 76.04 billion by 2032.

This blog will delve into the various factors driving the growth of the global AKI treatment market, the treatment options available, and the key players shaping the market landscape. We will also explore trends, growth drivers, challenges, and future outlook for the AKI treatment market.

Market Dynamics

Rising Incidence of Acute Kidney Injury

The increasing prevalence of AKI globally is one of the primary factors driving the growth of the market. Acute kidney injury can result from several causes, such as sepsis, cardiovascular conditions, dehydration, exposure to nephrotoxic drugs, or trauma. With the rise in the elderly population, which is more susceptible to these conditions, the incidence of AKI is also on the rise. According to estimates, the elderly population, particularly those over 60 years of age, is more prone to kidney damage due to multiple underlying conditions such as diabetes and hypertension, further driving the need for effective treatment options.

Advancements in Diagnostic Technologies

The development of more accurate and rapid diagnostic technologies is facilitating early diagnosis and better management of AKI. Novel biomarkers, imaging tools, and laboratory diagnostics are being developed to detect AKI earlier, allowing timely intervention and improved patient outcomes. This is also promoting the demand for advanced treatment solutions and technologies.

Growth in Dialysis and Renal Replacement Therapy

Dialysis and continuous renal replacement therapy (CRRT) are critical treatment modalities for AKI patients, especially in severe cases where the kidneys are no longer able to filter waste and fluids. The increasing use of dialysis, along with advancements in CRRT devices, is expected to boost market growth. CRRT is particularly beneficial for critically ill patients and has become a preferred treatment in many healthcare settings.

Supportive Government Initiatives and Reimbursement Policies

Governments in many countries are actively supporting efforts to improve the diagnosis and treatment of AKI through initiatives that focus on kidney health. Favorable reimbursement policies for dialysis and renal care procedures are further contributing to the expansion of the AKI treatment market.

Get a Free Sample Report with Table of Contents

Market Segmentation

Based on Treatment Type

1. Dialysis
2. Pharmacotherapy
3. Renal Replacement Therapy (RRT)
4. Supportive Care

The treatment landscape for AKI includes pharmacological interventions, dialysis, and renal replacement therapies. The availability of new drugs, coupled with innovations in dialysis technology, is improving the quality of care for AKI patients.

Key Players in the Global Acute Kidney Injury Treatment Market

Several companies are playing a pivotal role in the growth and development of the AKI treatment market. Let’s look at some of the prominent market players:

1. Angion

Angion Biomedica Corp. is a biopharmaceutical company focused on developing innovative therapies to treat acute organ injuries, including AKI. The company's flagship product, ANG-3777, is a hepatocyte growth factor (HGF) mimetic, currently being developed to reduce kidney damage in patients undergoing kidney transplantation or cardiac surgery. Angion’s research in the field of AKI is aimed at addressing the unmet need for therapies that can promote organ repair and improve survival rates.

ANG-3777 has shown promise in early-stage clinical trials, demonstrating the potential to accelerate recovery in AKI patients. By targeting pathways involved in tissue repair and inflammation, Angion is working to provide a much-needed therapeutic option for managing AKI.

2. AM-Pharma B.V.

AM-Pharma is a Dutch biopharmaceutical company specializing in the development of recombinant alkaline phosphatase (recAP) as a treatment for sepsis-associated AKI (SA-AKI). AKI is a common complication in sepsis patients, often resulting in poor outcomes. AM-Pharma's recAP aims to reduce kidney damage by modulating inflammation and protecting renal cells from injury.

The company’s innovative approach focuses on tackling the underlying causes of AKI in septic patients. AM-Pharma has successfully completed a Phase II trial for recAP, showing a significant reduction in kidney injury markers. This positions AM-Pharma as a leader in the development of novel therapies for AKI patients with sepsis.

3. Baxter International, Inc.

Baxter International is a global leader in dialysis products and renal care services, making a significant contribution to the AKI treatment market. The company offers a wide range of dialysis solutions, including peritoneal dialysis (PD) and continuous renal replacement therapy (CRRT) systems for critically ill patients.

Baxter’s portfolio includes the PrisMax CRRT system, which is designed to deliver customized dialysis and fluid management therapies. This advanced technology helps healthcare providers offer more precise and tailored care to AKI patients, improving their recovery outcomes. The company is also focused on expanding access to dialysis treatments in low-resource settings, helping more patients globally receive life-saving care.

4. Fresenius Medical Care Holdings, Inc.

Fresenius Medical Care is a major player in the global renal care industry, offering a comprehensive range of products and services for dialysis and renal care. The company provides both hemodialysis and peritoneal dialysis solutions for AKI patients, with a strong presence in hospitals, clinics, and home care settings.

Fresenius’ 4008S Next Generation Hemodialysis Machine is a cutting-edge device designed to provide efficient and comfortable dialysis for critically ill patients. The company is also investing in research and development to improve dialysis efficacy and patient comfort, ensuring that AKI patients receive optimal care.

Industry Trends

Increasing Adoption of Personalized Medicine

The trend toward personalized medicine is growing in the field of AKI treatment, as it allows for more tailored therapeutic approaches based on individual patient profiles. With the advent of precision diagnostics and biomarker development, healthcare providers can now identify the specific causes and severity of AKI, leading to better treatment outcomes.

Expansion of Home Dialysis and Remote Monitoring

Home dialysis is gaining traction as a preferred option for patients who require ongoing renal support. Advances in portable dialysis machines, along with the integration of telehealth and remote monitoring technologies, are making home dialysis a safer and more convenient option. This shift is expected to drive market growth as more patients opt for home-based treatment solutions.

Development of Regenerative Therapies

Innovations in regenerative medicine are opening new avenues for the treatment of AKI. Regenerative therapies aim to repair or replace damaged kidney tissue, reducing the need for dialysis or transplant in severe cases. Ongoing research into stem cell therapies and gene editing holds the potential to revolutionize AKI treatment by promoting kidney regeneration and functional recovery.

Challenges

High Treatment Costs

One of the major challenges in the AKI treatment market is the high cost of dialysis and renal replacement therapies. While these treatments are life-saving, they can be prohibitively expensive for many patients, especially in low-income regions. Ensuring affordable access to treatment remains a critical challenge for healthcare providers and governments.

Limited Availability of Donor Kidneys for Transplantation

Kidney transplantation remains the best long-term solution for patients with end-stage renal disease (ESRD), but the availability of donor kidneys is limited. The shortage of donors has created a backlog of patients waiting for transplants, which exacerbates the burden on dialysis and CRRT systems. Efforts to increase organ donation rates and develop alternatives, such as bioengineered kidneys, are ongoing.

Future Outlook

The global acute kidney injury treatment market is poised for steady growth, driven by rising incidence rates, advancements in treatment modalities, and supportive government initiatives. As new diagnostic and therapeutic innovations emerge, the market is expected to offer improved outcomes for AKI patients and provide more accessible treatment options.